RecruitingNCT06440330

Define Predictors for Posttransplant Diabetes Mellitus Study


Sponsor

University Hospital, Antwerp

Enrollment

330 participants

Start Date

Sep 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The primary aim of this prospective, multicentre study is to develop an accurate and convenient tool to predict the risk of PTDM at 3 months post-transplant, based on information on the day of transplantation (day 0). In order to create such model, we will start by identifying individual predictor variables at the day of transplantation and subsequently explore the optimal combination of these predictors in multivariable models. Secondary objectives include: * Compare the performance of the model based on predictor variables at day 0 with existing models for prediction of PTDM (Chakkera, San Antonio Diabetes Prediction Model and Framingham Offspring Study Diabetes Mellitus algorithm) * Explore the glucose level evolution during the first 2 weeks after transplantation using continuous glucose monitoring, and its relationship with baseline patient characteristics and immunosuppressant drug use. * Evaluate the added value of incorporating information on glucose levels in the first and second weeks post-transplant to improve the PTDM prediction model. * Identify predictors for early post-transplant hyperglycemia (first 2 weeks post-transplantation) * Explore the correlation between early post-transplant hyperglycemia (fasting glycemia, pre-dinner glycemia) and PTDM at 3 months


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adult patients (≥18 years) with end stage kidney disease undergoing kidney transplantation with a deceased or living donor
  • Signed informed consent
  • Initial therapy with at least tacrolimus and corticosteroids

Exclusion Criteria4

  • Patients with a diagnosis of diabetes mellitus (either type 1 or type 2) prior to kidney transplantation
  • Treatment with GLP1-RA for weight losing purposes
  • Patients receiving a multi-organ transplantation
  • ABO incompatibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEcontinuous glucose monitoring

continuous glucose monitoring will be used during the first 14 days post-transplantation


Locations(1)

UZA

Edegem, Antwerpen, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06440330


Related Trials